Cover Image
市場調查報告書

印度的診斷服務市場未來展望

Indian Diagnostic Services Market Outlook 2020

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 243950
出版日期 內容資訊 英文 130 pages
訂單完成後即時交付
價格
Back to Top
印度的診斷服務市場未來展望 Indian Diagnostic Services Market Outlook 2020
出版日期: 2016年05月01日 內容資訊: 英文 130 pages
簡介

本報告提供印度的診斷服務市場相關分析,最新的市場結構、趨勢,及今後的市場趨勢預測,各部門詳細趨勢,今後的策略發展的方向性,各種經營模式,消費者認知、行動,法規環境,主要企業簡介等調查、考察。

第1章 分析師的見解

第2章 分析方法

第3章 印度:宏觀經濟指標及人口組成指標

  • 醫療費
  • 醫療基礎設施
  • 巨大的人口為基礎的

第4章 市場動態

  • 推動因素
  • 課題
  • 機會
  • 市場趨勢

第5章 疾病負擔

  • 癌症
  • 心血管疾病
  • 結核
  • 瘧疾
  • HIV/AIDS
  • 糖尿病
  • 登革熱

第6章 診斷服務市場:現在、未來分析

  • 病理學服務
    • 市場預測
    • 主要部門分析
  • 放射線醫學服務
    • 市場預測
    • 主要部門分析

第7章 診斷服務市場:市場機會的評估

  • 診斷測試所:都市區、農村的分佈情形
  • 檢驗的成本評估:第一級、第二級城市的情況
    • 病理檢驗
    • 放射線檢驗
  • 私人、股權 (PE) 投資環境

第8章 診斷服務:經營模式

  • 公私合營 (PPP)
  • 單一的專用型號 (SSM:專業領域型模式)
  • 中心輻射型

第9章 在第一級、第二級城市的消費行為的研究

  • 第一級城市:診斷檢驗的支出劇增
  • 醫生推薦的檢驗所最受歡迎
  • 品牌的人氣:檢驗室的偏好的主要決策要素
  • 獨立型檢驗所:在調查受訪者中受歡迎
  • 民間檢驗設施比公營檢驗中心受歡迎
  • 中規模檢驗所:調查受訪者的目前選擇

第10章 法規環境:認證和品質保證

  • 商店、機構法的要求
  • NABL (全國檢驗、檢測設施認證委員會)的認證權限
  • NABL的認證過程
  • 診療所法(2010年)估計的影響

第11章 競爭環境 (產業概要、SWOT分析)

  • Super Religare Laboratories
  • Dr. Lal PathLabs
  • Metropolis Healthcare Limited
  • Thyrocare Technologies Limited
  • Quest Diagnostics India Private Limited,
  • PathCare Labs Pvt. Ltd.
  • Oncquest Laboratories Ltd.

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Diagnosis is the first step to disease management, as without accurate identification there is no possibility for accurate treatment. India is a land full of opportunities for players in the diagnostic service industry. The country has become one of the major destinations for various diagnostic services. Also, India's thriving economy is driving urbanization and developing an expanding middle class, with rising disposable incomes to spend on healthcare.

According to RNCOS' new research report “Indian Diagnostic Services Market Outlook 2020”, the diagnostic services market is expected to continue growing at 27.5% for next five years. This growth is likely to be driven by improving healthcare facilities, medical diagnostic and pathological laboratories, private-public projects, and the health insurance sector. Moreover, with the rise in health consciousness in the society and the rising burden of chronic diseases, this market will swell to approximately INR 860 Billion in revenues market by 2020.

Though a major portion of diagnostic business is being managed by the so called unorganized sector, the diagnostic service market is expected to become much more organized and consolidated with a lot of small and independent laboratory players becoming franchisees for the larger players. In order for clients and interested companies to enter this industry, our report provides an in-depth analysis of the cost assessment comparison of most common pathological and radiological tests among Tier I and Tier II cities.

RNCOS' present report provides an overview of the Indian diagnostic lab services market delivering an effective overview of the market size and future forecast. In terms of services, the market is dominated by pathology services, which account for approximately 70% of the market. The report additionally investigates the current market trends and opportunities with their impact on the performance of the sector. Further, the report provides consumer behavior patterns with respect to diagnostic services. Moreover, the report also provides insights regarding the prevalence and incidences of various diseases for which the diagnostic services are widely used.

The report also covers various business models in the Indian diagnostic services market, which generally scale up the level of diagnostic services and facilitate the entry of new market players. The report effectively assesses the implementation of commonly used models, such as PPP model, hub and spoke models, and even analyzes their impact in generating revenue. Moreover, RNCOS' industry experts prudently analyzed the regulatory and accreditation landscape with respect to setting up of diagnostic labs in Indian cities. The report, in this context, investigates into the viability of accrediting such diagnostics labs.

After an exhaustive study of the industry, the report presents a deep dive competitive landscape covering the top players along with business overview, strength-weakness analyses, recent developments, and growth strategies adopted by them to sustain their position in the Indian diagnostic services market.

Table of Contents

1. Analyst View

2. Research Methodology

3. India: Macro and Demographic Indicators

  • 3.1. Healthcare Spending
  • 3.2. Healthcare Infrastructure
  • 3.3. Huge Population Base

4. Market Dynamics

  • 4.1. Drivers
    • 4.1.1. Rising Demand of Preventive Care Diagnostics
    • 4.1.2. Rising Burden of Chronic Diseases
    • 4.1.3. Public - Private Partnership Models for Promoting Diagnostic Services
    • 4.1.4. Increasing Disposable Income
  • 4.2. Challenges
    • 4.2.1. Low Adoption of Advanced In-Vitro Diagnostic Technologies
    • 4.2.2. Lack of Proper Regulatory Framework
  • 4.3. Opportunities
    • 4.3.1. Increasing Investment by Foreign Companies
    • 4.3.2. Rise in Medical Tourism
    • 4.3.3. Tele-radiology: Prospective Service Facilitator for Remote Areas
    • 4.3.4. Emerging Tier II and Tier III cities
  • 4.4. Trends
    • 4.4.1. Increasing Automation Driving the Indian Diagnostic Services Market
    • 4.4.2. Inclination of Doctors towards Debt Financing
    • 4.4.3. Home Care Health Accessibility: Gaining Consumer Acceptance
    • 4.4.4. E-packages: New Way to Deliver Diagnostic Services
    • 4.4.5. Gene Based Testing Methods on the Rise

5. Disease Burden

  • 5.1. Cancer
  • 5.2. Cardiovascular Diseases
  • 5.3. Tuberculosis
  • 5.4. Malaria
  • 5.5. HIV/AIDS
  • 5.6. Diabetes Mellitus
  • 5.7. Dengue

6. Diagnostic Services Market: Current and Future Analysis

  • 6.1. Pathology Services
    • 6.1.1. Market Outlook
    • 6.1.2. Key Segment Analysis
  • 6.2. Radiology Services
    • 6.2.1. Market Outlook
    • 6.2.2. Key Segment Analysis

7. Diagnostic Services Market: Opportunity Assessment

  • 7.1. Diagnostics Laboratories: Urban and Rural Split
  • 7.2. Cost Assessment of Tests: Tier I and Tier II
    • 7.2.1. Pathological Tests
    • 7.2.2. Radiological Tests
  • 7.3. PE Investment Landscape

8. Diagnostic Services: Business Models

  • 8.1. Public Private Partnership (PPP)
    • 8.1.1. Understanding of Concept: Indian Scenario
    • 8.1.2. PPP Model in Healthcare and Diagnostic Services
    • 8.1.3. Key Healthcare and Diagnostics PPP Projects
    • 8.1.4. Case Study
  • 8.2. Single Specialty Model (SSM)
    • 8.2.1. Understanding the Concept: Indian Scenario
    • 8.2.2. Model's Key Advantages
    • 8.2.3. Case Study
  • 8.3. Hub and Spoke Model
    • 8.3.1. Understanding of Concept: Indian Scenario
    • 8.3.2. Model's Key Advantages
    • 8.3.3. Case Study

9. Consumer Behavior Research in Tier I and II

  • 9.1. Tier I: Spending Aggressively on Diagnostic Tests
  • 9.2. Physicians' Referred Labs Given Highest Preference
  • 9.3. Brand Popularity: Key Determinant for Lab Preference
  • 9.4. Independent Labs: Popular Among Respondents
  • 9.5. Private Lab Facilities Dominating Government Owned Centers
  • 9.6. Medium Scale Labs: Current Choice of the Respondents

10.Regulatory Environment: Accreditation and Quality Assurance

  • 10.1. Requirements for the Shop and Establishment Act
  • 10.2. NABL Accreditation Mandates
  • 10.3. NABL Accreditation Procedure
  • 10.4. Plausible Impact of the Clinical Establishments Act, 2010

11. Competitive Landscape (Business Overview, and Strength-Weakness Analysis)

  • 11.1. Super Religare Laboratories
  • 11.2. Dr. Lal PathLabs
  • 11.3. Metropolis Healthcare Limited
  • 11.4. Thyrocare Technologies Limited
  • 11.5. Quest Diagnostics India Private Limited,
  • 11.6. PathCare Labs Pvt. Ltd.
  • 11.7. Oncquest Laboratories Ltd.

List of Figures:

  • Figure 3-1: Healthcare Spending (US$ per head), 2015-2020
  • Figure 3-2: Consumer Healthcare Spending (Billion US$), 2015-2020
  • Figure 3-3: Share of Diagnostic Services in Total Healthcare Expenditure (%), 2015
  • Figure 3-4: Share of Public and Private Hospitals in Total Hospitals (%), 2015
  • Figure 3-5: Population (Million), 2015-2020
  • Figure 3-6: Population Breakup by Urban and Rural India (%), 2015
  • Figure 3-7: Middle Class Population (Million), 2015-2020
  • Figure 6-1: Share of Pathology and Radiology in Diagnostic Services Market (%), 2015
  • Figure 6-2: Share of Organized Diagnostic Services Market (%), 2015
  • Figure 6-3: Share of Organized Diagnostic Services Market (%), 2020
  • Figure 6-4: Diagnostic Services Market (Billion INR), 2015-2020
  • Figure 6-5: Pathology Services Market (Billion INR), 2015-2020
  • Figure 6-6: Share of Organized Pathology Services Market (%), 2020
  • Figure 6-7: Pathology Services Market by Segments (%), 2015
  • Figure 6-8: Radiology Services Market (Billion INR), 2015-2020
  • Figure 6-9: Share of Organized Radiology Services Market (%), 2020
  • Figure 6-10: Radiology Services Market by Segment (2015)
  • Figure 7-1: Percentage Breakup of Diagnostic Labs in Urban and Rural India
  • Figure 7-2: PE Investment in Key Sectors of Healthcare and Life Sciences (%), 2015
  • Figure 7-3: PE Investment (Million US$) and Number of Deals in Diagnostics, FY 2011-FY 2015
  • Figure 9-1: Tier-Wise Diagnostic Test Expenditure/Year
  • Figure 9-2: Consumer Preference for Physician Prescribed Lab
  • Figure 9-3: Factors Impacting Consumer Lab Preference
  • Figure 9-4: Consumer Preference by Lab Type (Independent/Hospital)
  • Figure 9-5: Consumer Preference by Lab Type (Government/Private)
  • Figure 9-6: Consumer Preference by Lab Type (Small/Medium/Large)
  • Figure 10-1: Flowchart for NABL Accreditation Procedure
  • Figure 11-1: Dr. Lal Path Labs - Breakup of Revenue by Region (%), 2015

List of Tables:

  • Table 3-1: Population Break-up by Age-Group (Million), 2015-2020
  • Table 5-1: Prevalence of Cancer (Million), 2013-2015
  • Table 5-2: Prevalence & Incidences of Tuberculosis (Million), 2013-2015
  • Table 5-3: Incidence of Malaria (Million), 2013-2015
  • Table 5-4: Prevalence of HIV/AIDS (Million), 2013-2015
  • Table 5-5: Prevalence of Diabetes (Million), 2013-2015
  • Table 5-6: Incidence of Dengue, 2013-2015
  • Table 7-1: Distribution of Diagnostic Labs in Urban Area (Class I to VI)
  • Table 7-2: Investigation Cost of Common Biochemical Tests in Tier I and Tier II (INR)
  • Table 7-3: Investigation Cost of Common Hematology Tests in Tier I and Tier II (INR)
  • Table 7-4: Investigation Cost of Common Immunology Tests in Tier I and Tier II (INR)
  • Table 7-5: Investigation Cost of Common Urinology Tests in Tier I and Tier II (INR)
  • Table 7-6: Investigation Cost of Common Coagulation Tests in Tier I and Tier II (INR)
  • Table 7-7: Investigation Cost of Common X-Ray Tests in Tier I and Tier II (INR)
  • Table 7-8: Investigation Cost of Common Ultrasound Tests in Tier I and Tier II (INR)
  • Table 7-9: Investigation Cost of Common MRI Tests in Tier I and Tier II (INR)
  • Table 7-10: Investigation Cost of Common CT Tests in Tier I and Tier II (INR)
  • Table 7-11: Investigation Cost of Common PET-CT Test in Tier I and Tier II (INR)
  • Table 8-1: Role of Key Stakeholders in Healthcare PPP Model
  • Table 8-2: Key Healthcare PPP Projects
  • Table 8-3: Key Diagnostic Services PPP Projects
  • Table 8-4: Advantages of Single Specialty Model in Diagnostic Services
  • Table 9-1: Characteristics of Sample Surveyed
  • Table 11-1: Dr. Lal Path Labs - Key Financials (Million INR), 2013-2015
  • Table 11-2: Quest Diagnostics - Key G2Financials (Million INR), 2013-2015
Back to Top